Research & Regulatory News

STRIDE and the Qualifier That Keeps Getting Dropped

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Bonaca and colleagues published STRIDE in the Lancet in May 2025: a phase 3b, double-blind randomised trial of semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes.

Key facts

Trial
STRIDE
Published
Lancet, 3 May 2025 (PMID 40169145)
Design
Phase 3b, double-blind, randomised
Population
Symptomatic PAD and type 2 diabetes
Endpoint
Walking capacity
Subgroup analysis
Rasouli 2025 (PMID 40543068)

The qualifier in the title

The trial enrolled people with symptomatic peripheral artery disease AND type 2 diabetes. That second criterion appears in the published title and is routinely dropped when the result is summarised as semaglutide improving walking in peripheral artery disease. It defines who the finding applies to, and dropping it widens the claim beyond what was studied.

Why walking capacity is the right endpoint

The defining symptom of peripheral artery disease is claudication, pain on walking that limits how far a person can go. Measuring walking distance tests the thing the condition actually does to people, rather than a surrogate such as an imaging measure or an ankle pressure index. It is a functional endpoint, which is generally harder to move and more meaningful when it does move.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why a functional endpoint is unusual in this literature

Most incretin trials report weight, glycaemic measures or event counts. A trial whose primary question is how far someone can walk is asking about capability rather than biology, and that connects to the body composition discussion elsewhere on this site: functional measures test whether a change in composition or physiology matters to what a person can do.

What the subgroup analysis examined

Rasouli and colleagues published on benefit by baseline type 2 diabetes characteristics in Diabetes Care in September 2025. Subgroup analyses within a randomised trial examine whether an effect is consistent across the enrolled population, and they are hypothesis-generating rather than definitive because the trial was not randomised within subgroups.

What this adds to the indication picture

Cardiovascular events in SELECT, kidney events in FLOW, liver histology in ESSENCE, heart failure in STEP-HFpEF and now walking capacity in peripheral artery disease. The pattern across these is a metabolic agent being assessed organ system by organ system, and reported as under regulatory review for indications beyond weight.

The boundary

Semaglutide is a licensed medicine and STRIDE was a registered randomised trial conducted under clinical supervision. Nothing supplied on this site is semaglutide or is an alternative to any treatment for peripheral artery disease.

Frequently asked questions

Who was enrolled in STRIDE?

People with symptomatic peripheral artery disease and type 2 diabetes. The diabetes criterion is in the published title and is often dropped in summaries.

Why measure walking capacity?

Claudication (pain limiting walking distance) is the defining symptom, so it tests what the condition actually does rather than a surrogate.

What did the subgroup analysis show?

Rasouli 2025 examined benefit by baseline diabetes characteristics. Subgroup analyses within a trial are hypothesis-generating rather than definitive.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.